Gevo Reports First Quarter 2021 Financial Results
SYNDICATED 8 hours ago Gevo to Host Conference Call Today at 4:30 p.m. EDT/2:30 p.m. MDTENGLEWOOD, Colo., May 13, 2021 (GLOBE NEWSWIRE) Gevo, Inc. (NASDAQ: GEVO) today announced financial results for the first quarter of 2021 and recent corporate highlights. Recent Corporate Highlights In January 2021, Gevo announced the plans for its innovative, world-class and novel Net-Zero 1 Project (“Net-Zero 1”) to be located in Lake Preston, South Dakota..
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate .
Strongbridge Biopharma plcMay 12, 2021 GMT
~ Reports KEVEYIS
®
(dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~
~ Reiterates Full-Year 2021 KEVEYIS
(dichlorphenamide) Revenue Guidance of Approximately $34 Million to $36 Million ~
~ Awaiting Day 74 Letter from U.S. Food & Drug Administration (FDA) for the Company’s New Drug Application (NDA) Submission for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome ~
~ Receives Notification from United States Patent and Trademark Office that it has Entered a Notice of Allowance Covering a Method of Treating Patients with Cushing’s Syndrome with RECORLEV® (levoketoconazole) ~
Calyxt Reports First Quarter 2021 Financial Results
Successful Transformation of Hemp Genome Enables Step Change in Calyxt s Innovation Approaches in the Species
Promoted Sarah Reiter to the newly created role of Chief Business Officer
Scientific Advisory Board Formed, Diverse Scientific Expertise, and Proprietary Insights to Support Company Growth
Management to Host Conference Call Today at 4:30 p.m. ET
ROSEVILLE, MN / ACCESSWIRE / May 6, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, today announced financial results for its first quarter ended March 31, 2021. The first several months of 2021 included several exciting developments in our laboratories, the promotion of Sarah Reiter to Chief Business Officer, and the formation of our Scientific Advisory Board, with the scientific and technical expertise to guide us through the evolution of plant-based technology, said Yves Ribeill, Ph.D., Executive Chair. We also continued to execute on products in our
Share:
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes
Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors
Management to Host Conference Call Today at 7:30 a.m. ET
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2021 and provided an update on company operations.
Recent Key Amarin Highlights:
Q1 net total revenue
: Net total revenue in the first quarter of 2021 was $142.2 million, consisting of $140.8 million in net product revenue from the United States, $0.5 million in net product revenue from outside the United States and $0.8 million in licensing and royalty revenue. Net product revenue from the United States declined $4.7 million,
vimarsana © 2020. All Rights Reserved.